In men with metastatic high‑volume hormone‑sensitive prostate adenocarcinoma, what is the benefit of adding docetaxel chemotherapy to standard androgen deprivation therapy (castration) plus an androgen‑receptor pathway inhibitor compared with androgen deprivation therapy plus an androgen‑receptor pathway inhibitor alone?

Triplet Therapy Provides Superior Survival in Metastatic High-Volume Hormone-Sensitive Prostate Cancer

For men with metastatic high-volume hormone-sensitive prostate adenocarcinoma, adding docetaxel to castration plus an androgen receptor pathway inhibitor (triplet therapy) significantly improves overall survival compared to castration plus ARPI alone, with a 25-32% reduction in mortality risk. 1, 2

Evidence for Triplet Therapy Superiority

Overall Survival Benefit

• Triplet therapy (ADT + ARPI + docetaxel) reduces the risk of death by 26% compared to ADT + docetaxel alone (HR 0.74; 95% CI 0.66-0.83, p < 0.00001) in pooled analysis of randomized trials 2

• The ARASENS trial demonstrated a 32% mortality reduction with darolutamide + ADT + docetaxel versus ADT + docetaxel (HR 0.68; 95% CI 0.57-0.80) 1

• The PEACE-1 trial showed a 25% mortality reduction with abiraterone + prednisone + ADT + docetaxel versus ADT + docetaxel (HR 0.75; 95% CI 0.59-0.95) 1, 2

High-Volume Disease Specific Benefits

• In high-volume disease specifically, triplet therapy reduces mortality by 24% (HR 0.76; 95% CI 0.59-0.97, p = 0.03) 2

• The ARASENS trial demonstrated consistent benefit in high-volume patients (HR 0.69; 95% CI 0.57-0.82) 1

• De novo metastatic disease shows even greater benefit with a 27% mortality reduction (HR 0.73; 95% CI 0.64-0.82, p < 0.00001) 2

Why Doublet Therapy (ADT + ARPI) Alone is Insufficient

Historical Context

• While ADT + abiraterone alone improved survival versus ADT in LATITUDE (HR 0.62) and STAMPEDE (HR 0.63), these trials did not include docetaxel 3

• ADT + docetaxel alone improved survival in CHAARTED for high-volume disease (HR 0.63; median OS 51.2 vs 34.4 months) 4

• No randomized trials have directly compared ADT + ARPI versus ADT + ARPI + docetaxel, but the triplet trials used ADT + docetaxel as the control arm and demonstrated additional benefit from adding ARPI 3

The Additive Effect

• Disease-free survival improves dramatically with triplet therapy (HR 0.41; 95% CI 0.35-0.49, p < 0.00001) compared to doublet therapy 2

• The 52-week PSA complete response rate reaches 61% with triplet therapy, and achieving this correlates with improved overall survival (HR 4.67 for those not achieving CR) 5

Clinical Implementation Algorithm

Patient Selection for Triplet Therapy

Offer triplet therapy to:

• All patients with high-volume disease (≥4 bone metastases with ≥1 outside vertebral column/pelvis, OR visceral metastases) who are chemotherapy candidates 3
• Patients with de novo metastatic disease regardless of volume 1, 2
• Patients with high-risk disease per LATITUDE criteria (Gleason ≥8, ≥3 bone lesions, or visceral metastases) 3

Specific Regimen

Standard triplet regimen:

• Docetaxel 75 mg/m² every 3 weeks for 6 cycles (not 2-weekly dosing) 6
• ARPI options: Darolutamide (preferred based on ARASENS data), abiraterone 1000 mg daily + prednisone 5 mg daily, or enzalutamide 3, 1
• Continuous ADT (LHRH agonist/antagonist or bilateral orchiectomy) 3

Toxicity Considerations

• Grade 3-5 adverse events occur in 42-52% of patients receiving triplet therapy, primarily from docetaxel-related neutropenia 7, 5

• Febrile neutropenia occurs in approximately 14% with standard 3-weekly docetaxel 8

• ARPI-specific toxicities: Hypertension (5-14%), transaminitis (6-13%) with abiraterone; fatigue with enzalutamide 7

• Dose reduction to 60 mg/m² is recommended if febrile neutropenia develops 8

Critical Pitfalls to Avoid

Do not use doublet therapy (ADT + ARPI alone) in high-volume disease patients who are chemotherapy candidates – this represents undertreatment given the magnitude of survival benefit from triplet therapy 1, 2

Do not substitute 2-weekly docetaxel dosing – all survival data supporting triplet therapy used the 3-weekly 75 mg/m² schedule for 6 cycles 6

Do not omit docetaxel based solely on age – fitness for chemotherapy, not chronological age, should guide decisions, as the survival benefit is substantial 3, 1

Do not use sequential therapy (ARPI followed by docetaxel at progression) instead of upfront triplet therapy – no evidence supports this approach provides equivalent outcomes 3

Strength of Evidence

The recommendation for triplet therapy over doublet therapy is based on Level 1 evidence from multiple phase III randomized controlled trials (ARASENS, PEACE-1) with consistent results across studies 1, 2. The ASCO guideline explicitly states that both docetaxel and abiraterone are separate standards of care, but their combination has not been assessed and cannot be recommended – however, this 2018 guideline predates the triplet therapy trials 3. The more recent evidence from 2022-2024 clearly demonstrates superiority of triplet therapy 1, 2.